The US Food and Drugs Administration has approved aliskiren (Tekturna®/Rasilez®) for the treatment of hypertension as monotherapy or in combination with other antihypertensive drugs. It will be available in 150mg and 300mg strengths. Aliskiren is the first in a new class of drugs called direct renin inhibitors. Manufacturer Novartis is awaiting a decision from the European Medicines Agency after a marketing application was filed in the EU in September 2006.
National Electronic Library for Medicine 06/03/2007